Celanese announces agreement with the population council for sustained release dual-API therapeutic

Celanese Corporation, a global speciality materials and chemical company, announced on 12 Sep 2023 that it has entered into an agreement with the Population Council to supply its VitalDose Drug Delivery Platform for use in a new Multipurpose Prevention Technology (MPT) Intravaginal Ring (IVR). The IVR is being developed to provide both contraception and protection against HIV and is currently in a phase 1b clinical trial. Long-acting continuous drug delivery dose forms, like IVRs, offer fewer barriers to reliable use than oral forms requiring daily doses. Providing benefits for patients, like enhanced convenience, can lead to better outcomes and is the driver for developing patient-centric dose forms. The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women's health for over two decades, offering tuneable and consistent elution for a variety of active pharmaceutical ingredient (API) molecules. The VitalDose Drug Delivery Platform provides reliable, controlled-release performance for a wide range of molecule types and has a long history of use in approved parenteral drug products in the United States, Europe and many other geographies. Original source: Celanese, website: http://www.celanese.com/, Copyright Celanese Corporation 2023.
sales agreement; drug delivery systems; pharmaceutical ingredients; VitalDose Drug Delivery Platform; [...]